Dawn Carter Bir - 06 Jul 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role
Chief Commercial Officer
Signature
/s/ Tracy Herson, attorney-in-fact
Issuer symbol
N/A
Transactions as of
06 Jul 2023
Net transactions value
$0
Form type
4
Filing time
10 Jul 2023, 16:42:40 UTC
Previous filing
02 Jun 2023
Next filing
01 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Award $0 +4,125 +13% $0.000000 35,010 06 Jul 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares represent Restricted Stock Units granted with performance criteria (PSUs). On December 17, 2020, the reporting person was granted 4,125 PSUs. On July 6, 2023, based on certain performance criteria, the PSUs vested as to 1,031 shares, with the remainder vesting 1/12th on each subsequent 3 month anniversary, subject to continued service through each vesting date.